13F Holdings
中文EN

NTHI NEONC TECHNOLOGIES HOLDINGS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1979414 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY12.0%
TTM EPS YoY25.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-642.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets241.6%
Debt / equity—
Current ratio0.38x
Interest coverage-15.69x

Cash quality & payout

Operating cash flow / net income0.48x
Accruals ratio-337.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$39,990$83,000
R&D expense$3.64M$3.05M
SG&A expense$4.82M$1.68M
Operating income-$58.24M-$7.14M
Interest expense$2.50M$2.56M
Net income-$62.15M-$11.90M
EPS (basic)-3.20-0.69
EPS (diluted)-3.20-0.69
Weighted avg. shares (diluted)19.40M17.34M
Balance sheet
Cash & equivalents$58,729$64,893
Current assets$1.39M$2.20M
Intangibles$500,000—
Total assets$2.82M$3.42M
Current liabilities$20.04M$8.92M
Total liabilities$20.33M$8.92M
Shareholders' equity-$17.51M-$5.50M
Shares outstanding21.99M18.09M
Cash flow statement
Operating cash flow-$20.36M-$4.21M
Capital expenditure$500,000—
Free cash flow-$20.86M—
Investing cash flow-$500,000—
Financing cash flow$20.86M$4.25M
Stock-based compensation$35.56M—

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.